Tech Company Financing Transactions
Armatus Bio Funding Round
On 5/6/2025, Armatus Bio announced $3 million in funding from Solve FSHD.
Transaction Overview
Company Name
Announced On
5/6/2025
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to support ARM-201, its AAV-delivered microRNA therapy designed to silence the expression of DUX4, the toxic protein responsible for muscle degeneration in individuals with FSHD.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
1275 Kinnear Road
Columbus, OH 43212
USA
Columbus, OH 43212
USA
Phone
Website
Email Address
Overview
Today's scientific advancements are raising the bar for tomorrow's life-changing medicines. Armatus is harnessing the promise of RNA technology to raise expectations for clinical outcomes in challenging neuromuscular diseases with no therapeutic options today. We are leveraging the power of vectorized RNAi to precisely target the genetic drivers of neurological and neuromuscular diseases with significant unmet needs.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Michael Triplett
Chief Executive Officer
Rachel Salzman
Chief Operating Officer
Peter Kleinhenz
Chief Scientific Officer
Scott Harper
Chief Technical Officer
Brian Price
Browse more venture capital transactions:
Prev: 5/6/2025: Finom venture capital transaction
Next: 5/6/2025: Orca AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to document all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs